Zymeworks, Inc. (ZYME)
25.15
-0.69
(-2.67%)
USD |
NASDAQ |
Nov 18, 12:41
Zymeworks EPS Diluted (Quarterly) : 2.278 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.278 |
| June 30, 2026 | -0.6168 |
| March 31, 2026 | -0.592 |
| December 31, 2025 | -0.547 |
| September 30, 2025 | -0.2587 |
| June 30, 2025 | 0.0299 |
| March 31, 2025 | -0.3033 |
| December 31, 2024 | -0.3148 |
| September 30, 2024 | -0.3921 |
| June 30, 2024 | -0.4933 |
| March 31, 2024 | -0.4179 |
| December 31, 2023 | -0.2045 |
| September 30, 2023 | -0.4065 |
| June 30, 2023 | -0.7603 |
| March 31, 2023 | -0.3649 |
| December 31, 2022 | 4.648 |
| September 30, 2022 | -0.7197 |
| June 30, 2022 | -0.9739 |
| March 31, 2022 | -1.183 |
| December 31, 2021 | -0.8396 |
| September 30, 2021 | -1.173 |
| June 30, 2021 | -1.313 |
| March 31, 2021 | -0.8681 |
| December 31, 2020 | -0.741 |
| September 30, 2020 | -1.426 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.7671 |
| March 31, 2020 | -0.6395 |
| December 31, 2019 | -1.657 |
| September 30, 2019 | -0.7015 |
| June 30, 2019 | -0.8855 |
| March 31, 2019 | -0.426 |
| December 31, 2018 | 0.2899 |
| September 30, 2018 | -0.5867 |
| June 30, 2018 | -0.22 |
| March 31, 2018 | -0.83 |
| December 31, 2017 | 1.28 |
| September 30, 2017 | -0.65 |
| June 30, 2017 | -0.63 |
| March 31, 2017 | -1.21 |
| December 31, 2016 | -0.4405 |
| September 30, 2016 | -0.4843 |
| June 30, 2016 | -0.29 |
| March 31, 2016 | -0.1059 |
| December 31, 2015 | -0.3105 |
| September 30, 2015 | -0.227 |
| June 30, 2015 | -0.1765 |
| March 31, 2015 | -0.0348 |
| December 31, 2014 | -0.1259 |
| September 30, 2014 | -0.1373 |
| June 30, 2014 | -0.1348 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| AbbVie, Inc. | 2.373 |
| Faeth Therapeutics, Inc. | -0.7894 |
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 173.70M |
| Revenue (Quarterly) | 256.46M |
| Total Expenses (Quarterly) | 82.76M |
| Enterprise Value | 2.403B |
| Gross Profit Margin (Quarterly) | 99.01% |
| Profit Margin (Quarterly) | 67.73% |
| Earnings Yield | 2.08% |
| Operating Earnings Yield | 2.35% |
| Normalized Earnings Yield | 2.088 |